Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03611621 · ClinicalTrials.gov registry record
A Follow up Study of Patients Treated With Imlifidase Prior to Kidney Transplantation
A clinical trial, sponsored by Hansa Biopharma AB.
- Completed
- Registry status
- 31
- Enrollment target
NCT03611621 is a clinical trial that has completed, run by Hansa Biopharma AB. The registered enrollment target is 31 participants.
The verdict
NCT03611621 has completed, sponsored by Hansa Biopharma AB.
- COMPLETED
- Registry status
- 31 participants
- Enrollment target
Study Summary
The rationale for the current protocol is to collect data from extended follow up in subjects that have received a kidney transplant following imlifidase dosing to provide a better understanding regarding the long-term outcome for these subjects. Data of parameters such as patient and graft survival, comorbidity, treatment of graft rejection episodes and quality of life as well as anti-drug antibody levels will be collected. This prospective, observational follow up study of subjects who have received imlifidase prior to kidney transplantation will provide important data to future prescribers and patients of the potential long-term benefits of imlifidase mediated transplantation.
Interventions
- DRUG Imlifidase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2018-06-27 |
| Est. Completion | 2023-02-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03611621
The ClinicalTrials.gov registry entry for NCT03611621 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hansa Biopharma AB, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Imlifidase is the first listed.
NCT03611621 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03611621 about?
NCT03611621 is a clinical study titled "A Follow up Study of Patients Treated With Imlifidase Prior to Kidney Transplantation". The rationale for the current protocol is to collect data from extended follow up in subjects that have received a kidney transplant following imlifidase dosing to provide a better understanding regarding the long-term outcome for these subjects. Data of parameters such as patient and graft survival...
What is the current status of trial NCT03611621?
This trial is currently completed. The enrollment target is 31 participants. The study started on 2018-06-27. Estimated completion is 2023-02-14.
What interventions are being tested in trial NCT03611621?
The interventions under investigation include: Imlifidase (DRUG).
Who is sponsoring clinical trial NCT03611621?
This trial is sponsored by Hansa Biopharma AB, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.